Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 22, 2018
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - September 22, 2018

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/22/18 - Aclaris Therapeutics to Attend Upcoming Investor Conferences [Ethiopian News Agency]
-Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced that management will attend the following conference:. Neal Walker, President and Chief...
9/22/18 - Bayer Receives Positive CHMP Opinion for Its Hemophilia a Treatment BAY94-9027
BAY94-9027 recently received FDA approval in the U.S. where it is marketed under the brand name Jivi (R). Oldenburg, Director of the Hemophilia Centre at the University Clinic in Bonn, Germany. After the approval of BAY94-9027 in the U.S., the positive CHMP recommendation is an important step forward for people with hemophilia A in the European Uni
9/22/18 - Bayer's Jivi Approved in Japan for Hemophilia a
Bayer, a pharmaceutical and life sciences company, issued the following news release:. Bayer announced today that the Japanese Ministry of Health, Labour and Welfare has approved Jivi (R) for the prophylactic treatment of hemophilia A for adults and adolescents 12 years of age or older in Japan. Teruhisa Fujii, director of the Blood Transfusion Div
9/22/18 - BeiGene Announces Preliminary Results from the Phase 1 Clinical Trial of Zanubrutinib in Chinese Patients with B-Cell Lymphoma at Annual Meeting of the Chinese Society of Clinical Oncology
BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today presented preliminary results from the Phase 1 trial of its investigational BTK inhibitor zanubrutinib in Chinese patients with B-cell lymphoma in an...
9/22/18 - BeiGene Presents Results on Anti-PD-1 Antibody Tislelizumab in Chinese Patients with Lung Cancers at the Annual Meeting of the Chinese Society of Clinical Oncology [Tehran Times (Iran)]
BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, presented clinical data on tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with lung cancers, in two oral presentations at the 21st...
9/22/18 - Boston Scientific Eluvia Drug-Eluting Stent Demonstrates Superior Results In IMPERIAL Trial
SAN DIEGO and MARLBOROUGH, Mass., Sept. 22, 2018/ PRNewswire/ Today, Boston Scientific announced positive 12- month data from the IMPERIAL trial, the first head-to-head drug-eluting stent trial in the superficial femoral artery. Results were presented during a late-breaking clinical trial session at the 30th Transcatheter Cardiovascular Therapeut
9/22/18 - British Pharmaceutical Industry Issues Statement on Avastin Treatment Case
The Association of the British Pharmaceutical Industry issued the following statement by Deputy Chief Scientific Officer Sheuli Porkess in response to the court case regarding the use of Avastin to treat a wet age-related macular degeneration:. "We will consider this judgement carefully. "As we exit the EU and the UK Government is looking for reg
9/22/18 - C20183865 Veterinary Medicines for Best People Caravan (Fisteval of Services) at Provincial Veterinarian`s Office
Company: PROVINCE OF DAVAO DEL NORTE. Emelene P. Coquilla, Administrative Asst. Description: Request for Quotation: C20183865 Veterinary Medicines for Best People Caravan at Provincial Veterinarian`s Office Closing Date/ Time: 27/09/2018 9:00 AM Area of Delivery: Davao Del Norte Procurement Mode: Shopping Brief: 1 39 Pail Multi-Vitamins with...
9/22/18 - Cardurion Pharmaceuticals Announces Initiation of Phase 1 Study of CRD-733, a PDE-9 Inhibitor in Development for the Treatment of Heart Failure [Sudan Tribune]
Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug Application for CRD-733, a Phosphodiesterase-9 inhibitor in development to improve...
9/22/18 - Congress Must Put People Before Pharmaceutical Company Profits
Earlier this year, as part of a bipartisan budget deal reached in Congress, policymakers agreed to increase the discounts the pharmaceutical industry must provide for drugs purchased in the Medicare Part D "donut hole" from 50 percent to 70 percent. "As Congress seeks to finalize bipartisan legislation to help address our nation's substance use di
9/22/18 - CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares [DesignMENA.com]
-CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 4,210,526 common shares at a public offering price of $47.50 per share, before underwriting discounts. CRISPR Therapeutics anticipates its gross proceeds.
9/22/18 - Data on Behcet Disease Detailed by Researchers at University Hospital (Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to...
Open-label multicenter study of ADA- treated patients with BD uveitis refractory to conventional immunosuppressants. " Our news editors obtained a quote from the research from University Hospital, "Sixty-five of 74 patients with uveitis due to BD, who achieved remission after a median ADA duration of 6 months. ADA was optimized in 23 of them.
9/22/18 - Denmark-copenhagen: Pharmaceutical Products [TendersInfo (India)]
Contract notice: Denmark- Copenhagen: Pharmaceutical products. The tender number includes the following medicines: Tender no: 1, Atc code: L04ab05, Generic name: Certolizumab pegol, Dispensing form: Injection, Strength: 200 mg, Packing: Syringe/ pen, Unit value: 14 mg, Quantity in units: 211 668. Reference is made to the terms of the tender terms.
9/22/18 - Dr. Jared Gollob Joins Kymera Therapeutics as Chief Medical Officer [News Central Asia]
Kymera Therapeutics LLC, a biotechnology company pioneering targeted protein degradation as a transformative new approach to creating breakthrough medicines for patients, today announced the appointment of Jared Gollob, MD, to the role of Chief Medical Officer. Formerly Vice President of Clinical Development and Global Vice President of Medical...
9/22/18 - DSP Clinical Research Named to Inc. 5000 List of Fastest Growing U.S. Private Companies for 5th Time [Sport360]
-Contract Research Organization DSP Clinical Research announced it achieved a ranking of 3500 on the prestigious Inc. 5000 list. DSP founder and President Darlene Panzitta said, "Were grateful to earn recognition from Inc. for the fifth time. DSP Clinical Research is a specialty Contract Research Organization dedicated to managing and executing Pha
9/22/18 - Fate Therapeutics Announces Pricing of Public Offering of Common Stock [FARS News Agency]
-Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing of an underwritten public offering of 9,259,260 shares of its common stock at a public offering price of $13.50 per share, before underwriting discounts
9/22/18 - FDA confirms second impurity in blood pressure drug [Sudan Tribune]
The FDA says its most recent testing of products shows an additional unexpected impurity in three lots of Valsartan produced by Torrent Pharmaceuticals. The FDA said it began testing for the second impurity after it learned that a Chinese drug company found NDEA in several batches of its valsartan API. However, the FDA tests showed that not all pro
9/22/18 - Findings from National Institute of Radiological Sciences Broaden Understanding of Radiopharmaceuticals (Radiopharmaceutical tracers for cardiac...
For more information on this research see: Radiopharmaceutical tracers for cardiac imaging. Journal of Nuclear Cardiology, 2018; 25: 1204-1236. Journal of Nuclear Cardiology can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. Our news correspondents report that additional information may be obtained by contacting K. Yoshinaga, Na
9/22/18 - Groups: Medicare discounts threatened in opioids bill Groups say Medicare discounts threatened in opioids bill
Republicans said Friday nothing has been decided in behind-the-scenes discussions. Details of the potential Medicare component were shifting, but basically it would partially roll back a 70 percent discount that Congress recently required drugmakers to provide to seniors in Medicare's "doughnut hole" coverage gap. "AARP strongly opposes... attempt
9/22/18 - Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab in Patients with Advanced Malignant Neuroendocrine Tumors at Annual Meeting of the Chinese Society of Clinical Oncology [Syrian Arab News Agency]
Innovent Biologics, Inc., a world-class China- based biopharmaceutical company that develops and commercializes high quality drugs, today presented clinical trial data from a phase Ib clinical trial that treated patients with neuroendocrine tumors who have failed of standard therapy with single agent sintilimab, a fully human anti-programmed cell..
9/22/18 - Keytruda Granted Priority Review by FDA for Treatment of Merkel Cell Carcinoma [Sport360]
The U.S. Food and Drug Administration granted priority review to Mercks supplemental Biologics License Application seeking accelerated approval for Keytruda as a treatment for adults and children with recurrent locally advanced or metastatic Merkel cell carcinoma. The regulatory agency set Dec. 28 as the deadline to reach a decision.
9/22/18 - Lonza Expands IbexTM Solutions to Offer Complete Product Lifecycle Management in One Location [Tehran Times (Iran)]
Lonza announces the addition of two new IbexTM Solutions offerings to Lonza`s 100,000 m2 biopark in Visp. In July 2017 IbexTMDedicate, a modular, technology-agnostic biomanufacturing concept, was launched as the first IbexTM Solutions offering. IbexTM Dedicate offers an innovative facility concept with reduced CAPEX and accelerated timelines, enabl
9/22/18 - MD Anderson Hosts Biden Cancer Community Summit
The University of Texas MD Anderson Cancer Center issued the following news release:. The University of Texas MD Anderson Cancer Center today joined with more than 450 communities and institutions across the country in hosting a Biden Cancer Community Summit, organized under the charge of the Biden Cancer Initiative. Jill Biden from Washington, D.C
9/22/18 - Medicine exports rise to $79 million
On Saturday, Mehrdad Aliyan, at the press conference of the fourth international fair of Iran Pharma Pharmaceuticals and related industries in Imam Khomeini's Mosalla, added,' There are several statistics available for export of medicines in Trade Development Organization; the export is mirror of domestic products given the state of the country fac
9/22/18 - Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere (meropenem and vaborbactam) [Sport360]
-Melinta Therapeutics, Inc., a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending Vabomere for approval as a treatment for...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415